A new advanced artificial intelligence (AI) algorithm more accurately model how genes associated with specific autoimmune diseases are expressed and regulated and to identify additional genes of risk.

Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...

Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

Exagen Inc. has appointed Dr. Michael Mahler as Chief Scientific Officer, recognizing his extensive expertise in immunology and autoimmune research. Dr. Mahler earned his Ph.D. from the University of ...

The global autoimmune disease testing market is witnessing steady expansion as healthcare systems intensify focus on early diagnosis and chronic disease management. Valued at USD 4.94 billion in 2025, ...

Autoimmune rheumatic diseases (ARDs) represent a diverse group of conditions in which the immune system mistakenly targets the body’s own tissues, often affecting the musculoskeletal system and ...